[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,481,526
  • Shares Outstanding, K 37,488
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ -3 M
  • EBITDA $ 21 M
  • 60-Month Beta 0.28
  • Price/Sales 5.43
  • Price/Cash Flow 45.67
  • Price/Book 99.12

Options Overview Details

View History
  • Implied Volatility 60.35% (-2.03%)
  • Historical Volatility 47.39%
  • IV Percentile 16%
  • IV Rank 17.80%
  • IV High 110.45% on 11/05/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 2) 1.62 (3.87%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 313
  • Volume Avg (30-Day) 375
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 42,930
  • Open Int (30-Day) 42,093
  • Expected Range 40.35 to 43.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 3
  • High Estimate $0.25
  • Low Estimate $0.01
  • Prior Year $0.33
  • Growth Rate Est. (year over year) -51.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.25 +13.99%
on 07/28/26
47.14 -12.35%
on 07/20/26
-5.33 (-11.43%)
since 07/17/26
3-Month
30.02 +37.64%
on 05/21/26
47.50 -13.01%
on 07/17/26
+10.64 (+34.68%)
since 05/19/26
52-Week
28.54 +44.78%
on 05/13/26
54.85 -24.67%
on 01/07/26
+3.09 (+8.08%)
since 08/19/25

Most Recent Stories

More News
Harrow: Q2 Earnings Snapshot

Harrow: Q2 Earnings Snapshot

HROW : 41.27 (+4.43%)
Harrow Announces Second Quarter 2026 Financial Results

Second Quarter 2026 and Selected Highlights:  Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year Reiterated full-year 2026 financial guidance of $350 million...

HROW : 41.27 (+4.43%)
Can Harrow's Specialty Pharma Model Withstand What the Guidance Is Quietly Signaling?

Barchart Research What to Expect from HROW Earnings HROW Generated August 7, 2026 Current Price $40.44 EPS Estimate $$-0.23 Consensus Rating Strong Buy Average Move 18.67% Can Harrow's Specialty Pharma...

HROW : 41.27 (+4.43%)
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive...

HROW : 41.27 (+4.43%)
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 41.27 (+4.43%)
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients,...

HROW : 41.27 (+4.43%)
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies...

HROW : 41.27 (+4.43%)
Harrow Announces Commercial Launch of BYOOVIZ® in the United States

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ®...

HROW : 41.27 (+4.43%)
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers ...

HROW : 41.27 (+4.43%)
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 41.27 (+4.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 42.30
2nd Resistance Point 41.22
1st Resistance Point 40.37
Last Price 41.27
1st Support Level 38.44
2nd Support Level 37.36
3rd Support Level 36.51

See More

52-Week High 54.85
Fibonacci 61.8% 44.80
Fibonacci 50% 41.70
Last Price 41.27
Fibonacci 38.2% 38.59
52-Week Low 28.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.